poisar

Stocks · News reference

Arbutus Biopharma Reports Third Quarter 2026 Financial Results and Corporate Update

Fiscal.ai

Arbutus Biopharma reported its third quarter 2026 financial results, highlighting a net income of $59.1 million and the lifting of a U.S. FDA clinical hold on its oral PD-L1 inhibitor, AB-101.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading